Cardiovascular Complications Associated with COVID-19: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Vivi Li and Version 1 by ANINDITA DAS.

An infectious coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is accompanied with elevated risk and adverse outcome among infected patients, even sudden death due to significant multiple organ dysfunction, including dire cardiovascular complications. Myocardial impairment due to invasion of SARS-CoV-2 virus via angiotensin-converting enzyme 2 receptor to cardiovascular cells/tissue leads to endothelial inflammation and dysfunction, de-stabilization of vulnerable atherosclerotic plaques, stent thrombosis and cardiac stress, caused by diminished oxygen supply and cardiac muscle damage and myocardial infarction. A number of promising therapeutic approaches are currently under clinical trials to avoid a massive surge of COVID-19 patients with prevalence of adverse cardiac events.

  • cardiovascular diseases
  • COVID-19
  • treatment strategies
  • angiotensin-converting enzyme 2 receptor
  • Hypertension
  • Myocardial Injury and Heart Failure
  • Myocarditis
  • Myocardial Arrhythmias
Please wait, diff process is still running!

References

  1. Mousavizadeh, L.; Ghasemi, S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 2020, 10.1016/j.jmii.2020.03.022. doi:10.1016/j.jmii.2020.03.022.
  2. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497-506. doi:10.1016/S0140-6736(20)30183-5.
  3. Chen, Y.; Liu, Q.; Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020, 92, 418-423. doi:10.1002/jmv.25681.
  4. Ong, S.W.X.; Tan, Y.K.; Chia, P.Y.; Lee, T.H.; Ng, O.T.; Wong, M.S.Y.; Marimuthu, K. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA 2020, 10.1001/jama.2020.3227. doi:10.1001/jama.2020.3227.
  5. Perlman, S.; Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009, 7, 439-450. doi:10.1038/nrmicro2147.
  6. Duan, K.; Liu, B.; Li, C.; Zhang, H.; Yu, T.; Qu, J.; Zhou, M.; Chen, L.; Meng, S.; Hu, Y.; Peng, C.; Yuan, M.; Huang, J.; Wang, Z.; Yu, J.; Gao, X.; Wang, D.; Yu, X.; Li, L.; Zhang, J.; Wu, X.; Li, B.; Xu, Y.; Chen, W.; Peng, Y.; Hu, Y.; Lin, L.; Liu, X.; Huang, S.; Zhou, Z.; Zhang, L.; Wang, Y.; Zhang, Z.; Deng, K.; Xia, Z.; Gong, Q.; Zhang, W.; Zheng, X.; Liu, Y.; Yang, H.; Zhou, D.; Yu, D.; Hou, J.; Shi, Z.; Chen, S.; Chen, Z.; Zhang, X.; Yang, X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020, 117, 9490-9496. doi:10.1073/pnas.2004168117.
  7. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020, 12, 8. doi:10.1038/s41368-020-0074-x.
  8. Gemmati, D.; Bramanti, B.; Serino, M.L.; Secchiero, P.; Zauli, G.; Tisato, V. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? Int J Mol Sci 2020, 21. doi:10.3390/ijms21103474.
  9. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; Li, W.W.; Li, V.W.; Mentzer, S.J.; Jonigk, D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020, 383, 120-128. doi:10.1056/NEJMoa2015432.
  10. Collaborative, C.O. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 2020, 396, 27-38. doi:10.1016/S0140-6736(20)31182-X.
  11. Ullah, W.; Saeed, R.; Sarwar, U.; Patel, R.; Fischman, D.L. COVID-19 Complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure. JACC Case Rep 2020, 2, 1379-1382. doi:10.1016/j.jaccas.2020.04.008.
  12. Guo, J.; Huang, Z.; Lin, L.; Lv, J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc 2020, 9, e016219. doi:10.1161/JAHA.120.016219.
  13. Turner, A.J.; Hiscox, J.A.; Hooper, N.M. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004, 25, 291-294. doi:10.1016/j.tips.2004.04.001.
  14. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; and the Northwell, C.-R.C.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; Cohen, S.L.; Cookingham, J.; Coppa, K.; Diefenbach, M.A.; Dominello, A.J.; Duer-Hefele, J.; Falzon, L.; Gitlin, J.; Hajizadeh, N.; Harvin, T.G.; Hirschwerk, D.A.; Kim, E.J.; Kozel, Z.M.; Marrast, L.M.; Mogavero, J.N.; Osorio, G.A.; Qiu, M.; Zanos, T.P. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020, 10.1001/jama.2020.6775. doi:10.1001/jama.2020.6775.
  15. Guo, T.; Fan, Y.; Chen, M.; Wu, X.; Zhang, L.; He, T.; Wang, H.; Wan, J.; Wang, X.; Lu, Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020, 10.1001/jamacardio.2020.1017. doi:10.1001/jamacardio.2020.1017.
  16. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, 395, 1054-1062. doi:10.1016/S0140-6736(20)30566-3.
  17. Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020, 10.1001/jamacardio.2020.0950. doi:10.1001/jamacardio.2020.0950.
  18. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020, 46, 846-848. doi:10.1007/s00134-020-05991-x.
  19. Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F.X.; Chong, M.; Lee, M. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 2020, 10.1001/jama.2020.4326. doi:10.1001/jama.2020.4326.
  20. Wang, C.J.; Ng, C.Y.; Brook, R.H. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. JAMA 2020, 10.1001/jama.2020.3151. doi:10.1001/jama.2020.3151.
  21. Vaduganathan, M.; Vardeny, O.; Michel, T.; McMurray, J.J.V.; Pfeffer, M.A.; Solomon, S.D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020, 382, 1653-1659. doi:10.1056/NEJMsr2005760.
  22. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; Du, B.; Li, L.J.; Zeng, G.; Yuen, K.Y.; Chen, R.C.; Tang, C.L.; Wang, T.; Chen, P.Y.; Xiang, J.; Li, S.Y.; Wang, J.L.; Liang, Z.J.; Peng, Y.X.; Wei, L.; Liu, Y.; Hu, Y.H.; Peng, P.; Wang, J.M.; Liu, J.Y.; Chen, Z.; Li, G.; Zheng, Z.J.; Qiu, S.Q.; Luo, J.; Ye, C.J.; Zhu, S.Y.; Zhong, N.S.; China Medical Treatment Expert Group for, C. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020, 382, 1708-1720. doi:10.1056/NEJMoa2002032.
  23. Centers for Disease Control and Prevention, N.C.f.H.S. Weekly Updates by Select Demographic and Geographic Characteristics. 2020, https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#Comorbidities.
  24. Dostal, D.E.; Baker, K.M. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999, 85, 643-650. doi:10.1161/01.res.85.7.643.
  25. Zores, F.; Rebeaud, M.E. COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious? Front Cardiovasc Med 2020, 7, 71. doi:10.3389/fcvm.2020.00071.
  26. Olkowicz, M.; Chlopicki, S.; Smolenski, R.T. Perspectives for angiotensin profiling with liquid chromatography/mass spectrometry to evaluate ACE/ACE2 balance in endothelial dysfunction and vascular pathologies. Pharmacol Rep 2015, 67, 778-785. doi:10.1016/j.pharep.2015.03.017.
  27. Fraga-Silva, R.A.; Sorg, B.S.; Wankhede, M.; Dedeugd, C.; Jun, J.Y.; Baker, M.B.; Li, Y.; Castellano, R.K.; Katovich, M.J.; Raizada, M.K.; Ferreira, A.J. ACE2 activation promotes antithrombotic activity. Mol Med 2010, 16, 210-215. doi:10.2119/molmed.2009.00160.
  28. Epelman, S.; Tang, W.H.; Chen, S.Y.; Van Lente, F.; Francis, G.S.; Sen, S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008, 52, 750-754. doi:10.1016/j.jacc.2008.02.088.
  29. Tomasoni, D.; Italia, L.; Adamo, M.; Inciardi, R.M.; Lombardi, C.M.; Solomon, S.D.; Metra, M. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail 2020, 22, 957-966. doi:10.1002/ejhf.1871.
  30. Basu, R.; Poglitsch, M.; Yogasundaram, H.; Thomas, J.; Rowe, B.H.; Oudit, G.Y. Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. J Am Coll Cardiol 2017, 69, 805-819. doi:10.1016/j.jacc.2016.11.064.
  31. Oudit, G.Y.; Pfeffer, M.A. Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19. Eur Heart J 2020, 41, 1818-1820. doi:10.1093/eurheartj/ehaa414.
  32. Zhang, H.; Penninger, J.M.; Li, Y.; Zhong, N.; Slutsky, A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020, 46, 586-590. doi:10.1007/s00134-020-05985-9.
  33. Khan, A.; Benthin, C.; Zeno, B.; Albertson, T.E.; Boyd, J.; Christie, J.D.; Hall, R.; Poirier, G.; Ronco, J.J.; Tidswell, M.; Hardes, K.; Powley, W.M.; Wright, T.J.; Siederer, S.K.; Fairman, D.A.; Lipson, D.A.; Bayliffe, A.I.; Lazaar, A.L. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care 2017, 21, 234. doi:10.1186/s13054-017-1823-x.
  34. Batlle, D.; Wysocki, J.; Satchell, K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond) 2020, 134, 543-545. doi:10.1042/CS20200163.
  35. Sama, I.E.; Ravera, A.; Santema, B.T.; van Goor, H.; Ter Maaten, J.M.; Cleland, J.G.F.; Rienstra, M.; Friedrich, A.W.; Samani, N.J.; Ng, L.L.; Dickstein, K.; Lang, C.C.; Filippatos, G.; Anker, S.D.; Ponikowski, P.; Metra, M.; van Veldhuisen, D.J.; Voors, A.A. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J 2020, 41, 1810-1817. doi:10.1093/eurheartj/ehaa373.
  36. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; Song, J.; Wang, S.; Chao, Y.; Yang, Z.; Xu, J.; Zhou, X.; Chen, D.; Xiong, W.; Xu, L.; Zhou, F.; Jiang, J.; Bai, C.; Zheng, J.; Song, Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020, 10.1001/jamainternmed.2020.0994. doi:10.1001/jamainternmed.2020.0994.
  37. Inciardi, R.M.; Lupi, L.; Zaccone, G.; Italia, L.; Raffo, M.; Tomasoni, D.; Cani, D.S.; Cerini, M.; Farina, D.; Gavazzi, E.; Maroldi, R.; Adamo, M.; Ammirati, E.; Sinagra, G.; Lombardi, C.M.; Metra, M. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020, 10.1001/jamacardio.2020.1096. doi:10.1001/jamacardio.2020.1096.
  38. Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020, 10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648.
  39. Epidemiology Working Group for Ncip Epidemic Response, C.C.f.D.C.; Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020, 41, 145-151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003.
  40. Li, J.; Wang, X.; Chen, J.; Zhang, H.; Deng, A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol 2020, 10.1001/jamacardio.2020.1624. doi:10.1001/jamacardio.2020.1624.
  41. Krittanawong, C.; Virk, H.U.H.; Narasimhan, B.; Wang, Z.; Narasimhan, H.; Zhang, H.J.; Sun, T.; Messerli, F.H. Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis. Prog Cardiovasc Dis 2020, 10.1016/j.pcad.2020.05.001. doi:10.1016/j.pcad.2020.05.001.
  42. Grasselli, G.; Zangrillo, A.; Zanella, A.; Antonelli, M.; Cabrini, L.; Castelli, A.; Cereda, D.; Coluccello, A.; Foti, G.; Fumagalli, R.; Iotti, G.; Latronico, N.; Lorini, L.; Merler, S.; Natalini, G.; Piatti, A.; Ranieri, M.V.; Scandroglio, A.M.; Storti, E.; Cecconi, M.; Pesenti, A.; Network, C.-L.I.; Nailescu, A.; Corona, A.; Zangrillo, A.; Protti, A.; Albertin, A.; Forastieri Molinari, A.; Lombardo, A.; Pezzi, A.; Benini, A.; Scandroglio, A.M.; Malara, A.; Castelli, A.; Coluccello, A.; Micucci, A.; Pesenti, A.; Sala, A.; Alborghetti, A.; Antonini, B.; Capra, C.; Troiano, C.; Roscitano, C.; Radrizzani, D.; Chiumello, D.; Coppini, D.; Guzzon, D.; Costantini, E.; Malpetti, E.; Zoia, E.; Catena, E.; Agosteo, E.; Barbara, E.; Beretta, E.; Boselli, E.; Storti, E.; Harizay, F.; Della Mura, F.; Lorini, F.L.; Donato Sigurta, F.; Marino, F.; Mojoli, F.; Rasulo, F.; Grasselli, G.; Casella, G.; De Filippi, G.; Castelli, G.; Aldegheri, G.; Gallioli, G.; Lotti, G.; Albano, G.; Landoni, G.; Marino, G.; Vitale, G.; Battista Perego, G.; Evasi, G.; Citerio, G.; Foti, G.; Natalini, G.; Merli, G.; Sforzini, I.; Bianciardi, L.; Carnevale, L.; Grazioli, L.; Cabrini, L.; Guatteri, L.; Salvi, L.; Dei Poli, M.; Galletti, M.; Gemma, M.; Ranucci, M.; Riccio, M.; Borelli, M.; Zambon, M.; Subert, M.; Cecconi, M.; Mazzoni, M.G.; Raimondi, M.; Panigada, M.; Belliato, M.; Bronzini, N.; Latronico, N.; Petrucci, N.; Belgiorno, N.; Tagliabue, P.; Cortellazzi, P.; Gnesin, P.; Grosso, P.; Gritti, P.; Perazzo, P.; Severgnini, P.; Ruggeri, P.; Sebastiano, P.; Covello, R.D.; Fernandez-Olmos, R.; Fumagalli, R.; Keim, R.; Rona, R.; Valsecchi, R.; Cattaneo, S.; Colombo, S.; Cirri, S.; Bonazzi, S.; Greco, S.; Muttini, S.; Langer, T.; Alaimo, V.; Viola, U. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020, 10.1001/jama.2020.5394. doi:10.1001/jama.2020.5394.
  43. Fang, L.; Karakiulakis, G.; Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020, 8, e21. doi:10.1016/S2213-2600(20)30116-8.
  44. Sun, M.L.; Yang, J.M.; Sun, Y.P.; Su, G.H. [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020, 43, 219-222. doi:10.3760/cma.j.issn.1001-0939.2020.03.016.
  45. Furuhashi, M.; Moniwa, N.; Mita, T.; Fuseya, T.; Ishimura, S.; Ohno, K.; Shibata, S.; Tanaka, M.; Watanabe, Y.; Akasaka, H.; Ohnishi, H.; Yoshida, H.; Takizawa, H.; Saitoh, S.; Ura, N.; Shimamoto, K.; Miura, T. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015, 28, 15-21. doi:10.1093/ajh/hpu086.
  46. Mancia, G.; Rea, F.; Ludergnani, M.; Apolone, G.; Corrao, G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020, 382, 2431-2440. doi:10.1056/NEJMoa2006923.
  47. Jarcho, J.A.; Ingelfinger, J.R.; Hamel, M.B.; D'Agostino, R.B., Sr.; Harrington, D.P. Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19. N Engl J Med 2020, 382, 2462-2464. doi:10.1056/NEJMe2012924.
  48. Reynolds, H.R.; Adhikari, S.; Pulgarin, C.; Troxel, A.B.; Iturrate, E.; Johnson, S.B.; Hausvater, A.; Newman, J.D.; Berger, J.S.; Bangalore, S.; Katz, S.D.; Fishman, G.I.; Kunichoff, D.; Chen, Y.; Ogedegbe, G.; Hochman, J.S. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020, 382, 2441-2448. doi:10.1056/NEJMoa2008975.
  49. Oudit, G.Y.; Kassiri, Z.; Jiang, C.; Liu, P.P.; Poutanen, S.M.; Penninger, J.M.; Butany, J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009, 39, 618-625. doi:10.1111/j.1365-2362.2009.02153.x.
  50. Mehra, M.R.; Ruschitzka, F. COVID-19 Illness and Heart Failure: A Missing Link? JACC Heart Fail 2020, 8, 512-514. doi:10.1016/j.jchf.2020.03.004.
  51. Warren-Gash, C.; Smeeth, L.; Hayward, A.C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009, 9, 601-610. doi:10.1016/S1473-3099(09)70233-6.
  52. Nguyen, J.L.; Yang, W.; Ito, K.; Matte, T.D.; Shaman, J.; Kinney, P.L. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol 2016, 1, 274-281. doi:10.1001/jamacardio.2016.0433.
  53. Das, A.; Smolenski, A.; Lohmann, S.M.; Kukreja, R.C. Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J Biol Chem 2006, 281, 38644-38652. doi:10.1074/jbc.M606142200.
  54. Saraste, A.; Pulkki, K.; Kallajoki, M.; Henriksen, K.; Parvinen, M.; Voipio-Pulkki, L.M. Apoptosis in human acute myocardial infarction. Circulation 1997, 95, 320-323. doi:10.1161/01.cir.95.2.320.
  55. Heusch, G.; Gersh, B.J. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 2017, 38, 774-784. doi:10.1093/eurheartj/ehw224.
  56. Klok, F.A.; Kruip, M.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; Endeman, H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020, 191, 145-147. doi:10.1016/j.thromres.2020.04.013.
  57. Stefanini, G.G.; Montorfano, M.; Trabattoni, D.; Andreini, D.; Ferrante, G.; Ancona, M.; Metra, M.; Curello, S.; Maffeo, D.; Pero, G.; Cacucci, M.; Assanelli, E.; Bellini, B.; Russo, F.; Ielasi, A.; Tespili, M.; Danzi, G.B.; Vandoni, P.; Bollati, M.; Barbieri, L.; Oreglia, J.; Lettieri, C.; Cremonesi, A.; Carugo, S.; Reimers, B.; Condorelli, G.; Chieffo, A. ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. Circulation 2020, 141, 2113-2116. doi:10.1161/CIRCULATIONAHA.120.047525.
  58. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020, 10.1001/jama.2020.1585. doi:10.1001/jama.2020.1585.
  59. Tersalvi, G.; Vicenzi, M.; Calabretta, D.; Biasco, L.; Pedrazzini, G.; Winterton, D. Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. J Card Fail 2020, 26, 470-475. doi:10.1016/j.cardfail.2020.04.009.
  60. Chen, T.; Wu, D.; Chen, H.; Yan, W.; Yang, D.; Chen, G.; Ma, K.; Xu, D.; Yu, H.; Wang, H.; Wang, T.; Guo, W.; Chen, J.; Ding, C.; Zhang, X.; Huang, J.; Han, M.; Li, S.; Luo, X.; Zhao, J.; Ning, Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020, 368, m1091. doi:10.1136/bmj.m1091.
  61. Dong, N.; Cai, J.; Zhou, Y.; Liu, J.; Li, F. End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV. JACC Heart Fail 2020, 8, 515-517. doi:10.1016/j.jchf.2020.04.001.
  62. Tavazzi, G.; Pellegrini, C.; Maurelli, M.; Belliato, M.; Sciutti, F.; Bottazzi, A.; Sepe, P.A.; Resasco, T.; Camporotondo, R.; Bruno, R.; Baldanti, F.; Paolucci, S.; Pelenghi, S.; Iotti, G.A.; Mojoli, F.; Arbustini, E. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 2020, 22, 911-915. doi:10.1002/ejhf.1828.
  63. Markousis-Mavrogenis, G.; Tromp, J.; Ouwerkerk, W.; Devalaraja, M.; Anker, S.D.; Cleland, J.G.; Dickstein, K.; Filippatos, G.S.; van der Harst, P.; Lang, C.C.; Metra, M.; Ng, L.L.; Ponikowski, P.; Samani, N.J.; Zannad, F.; Zwinderman, A.H.; Hillege, H.L.; van Veldhuisen, D.J.; Kakkar, R.; Voors, A.A.; van der Meer, P. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail 2019, 21, 965-973. doi:10.1002/ejhf.1482.
  64. van der Pol, A.; van Gilst, W.H.; Voors, A.A.; van der Meer, P. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail 2019, 21, 425-435. doi:10.1002/ejhf.1320.
  65. Almufleh, A.; Ahluwalia, M.; Givertz, M.M.; Weintraub, J.; Young, M.; Cooper, I.; Shea, E.L.; Mehra, M.R.; Desai, A.S. Short-term Outcomes in Ambulatory Heart Failure during the COVID-19 Pandemic: Insights from Pulmonary Artery Pressure Monitoring. J Card Fail 2020, 26, 633-634. doi:10.1016/j.cardfail.2020.05.021.
  66. Colivicchi, F.; Di Fusco, S.A.; Magnanti, M.; Cipriani, M.; Imperoli, G. The Impact of the Coronavirus Disease-2019 Pandemic and Italian Lockdown Measures on Clinical Presentation and Management of Acute Heart Failure. J Card Fail 2020, 26, 464-465. doi:10.1016/j.cardfail.2020.05.007.
  67. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020, 18, 844-847. doi:10.1111/jth.14768.
  68. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020, 18, 1094-1099. doi:10.1111/jth.14817.
  69. Sun, H.; Wang, X.; Degen, J.L.; Ginsburg, D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009, 113, 1358-1364. doi:10.1182/blood-2008-07-170506.
  70. Cooper, L.T., Jr. Myocarditis. N Engl J Med 2009, 360, 1526-1538. doi:10.1056/NEJMra0800028.
  71. Siddiqi, H.K.; Mehra, M.R. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020, 39, 405-407. doi:10.1016/j.healun.2020.03.012.
  72. Doyen, D.; Moceri, P.; Ducreux, D.; Dellamonica, J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet 2020, 395, 1516. doi:10.1016/S0140-6736(20)30912-0.
  73. Kochi, A.N.; Tagliari, A.P.; Forleo, G.B.; Fassini, G.M.; Tondo, C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020, 31, 1003-1008. doi:10.1111/jce.14479.
  74. Kochav, S.M.; Coromilas, E.; Nalbandian, A.; Ranard, L.S.; Gupta, A.; Chung, M.K.; Gopinathannair, R.; Biviano, A.B.; Garan, H.; Wan, E.Y. Cardiac Arrhythmias in COVID-19 Infection. Circ Arrhythm Electrophysiol 2020, 13, e008719. doi:10.1161/CIRCEP.120.008719.
  75. Lakkireddy, D.R.; Chung, M.K.; Gopinathannair, R.; Patton, K.K.; Gluckman, T.J.; Turagam, M.; Cheung, J.; Patel, P.; Sotomonte, J.; Lampert, R.; Han, J.K.; Rajagopalan, B.; Eckhardt, L.; Joglar, J.; Sandau, K.; Olshansky, B.; Wan, E.; Noseworthy, P.A.; Leal, M.; Kaufman, E.; Gutierrez, A.; Marine, J.E.; Wang, P.J.; Russo, A.M. Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Circulation 2020, 141, e823-e831. doi:10.1161/CIRCULATIONAHA.120.047063.
  76. Hu, H.; Ma, F.; Wei, X.; Fang, Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020, 10.1093/eurheartj/ehaa190. doi:10.1093/eurheartj/ehaa190.
  77. Puntmann, V.O.; Carerj, M.L.; Wieters, I.; Fahim, M.; Arendt, C.; Hoffmann, J.; Shchendrygina, A.; Escher, F.; Vasa-Nicotera, M.; Zeiher, A.M.; Vehreschild, M.; Nagel, E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020, 10.1001/jamacardio.2020.3557. doi:10.1001/jamacardio.2020.3557.
  78. Lindner, D.; Fitzek, A.; Brauninger, H.; Aleshcheva, G.; Edler, C.; Meissner, K.; Scherschel, K.; Kirchhof, P.; Escher, F.; Schultheiss, H.P.; Blankenberg, S.; Puschel, K.; Westermann, D. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol 2020, 10.1001/jamacardio.2020.3551. doi:10.1001/jamacardio.2020.3551.
  79. Sharma, A.; Garcia, G.; Arumugaswami, V.; Svendsen, C.N. Human iPSC-Derived Cardiomyocytes are Susceptible to SARS-CoV-2 Infection. bioRxiv 2020, 10.1101/2020.04.21.051912. doi:10.1101/2020.04.21.051912.
  80. Chen, C.; Zhou, Y.; Wang, D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz 2020, 45, 230-232. doi:10.1007/s00059-020-04909-z.
  81. Zheng, Y.Y.; Ma, Y.T.; Zhang, J.Y.; Xie, X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020, 17, 259-260. doi:10.1038/s41569-020-0360-5.
  82. Blyszczuk, P. Myocarditis in Humans and in Experimental Animal Models. Front Cardiovasc Med 2019, 6, 64. doi:10.3389/fcvm.2019.00064.
  83. Guzik, T.J.; Mohiddin, S.A.; Dimarco, A.; Patel, V.; Savvatis, K.; Marelli-Berg, F.M.; Madhur, M.S.; Tomaszewski, M.; Maffia, P.; D'Acquisto, F.; Nicklin, S.A.; Marian, A.J.; Nosalski, R.; Murray, E.C.; Guzik, B.; Berry, C.; Touyz, R.M.; Kreutz, R.; Wang, D.W.; Bhella, D.; Sagliocco, O.; Crea, F.; Thomson, E.C.; McInnes, I.B. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020, 116, 1666-1687. doi:10.1093/cvr/cvaa106.
  84. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020, 181, 281-292 e286. doi:10.1016/j.cell.2020.02.058.
  85. Fortini, F.; Vieceli Dalla Sega, F.; Caliceti, C.; Lambertini, E.; Pannuti, A.; Peiffer, D.S.; Balla, C.; Rizzo, P. Estrogen-mediated protection against coronary heart disease: The role of the Notch pathway. J Steroid Biochem Mol Biol 2019, 189, 87-100. doi:10.1016/j.jsbmb.2019.02.008.
  86. Ferrari, R.; Rizzo, P. The Notch pathway: a novel target for myocardial remodelling therapy? Eur Heart J 2014, 35, 2140-2145. doi:10.1093/eurheartj/ehu244.
  87. Gude, N.; Joyo, E.; Toko, H.; Quijada, P.; Villanueva, M.; Hariharan, N.; Sacchi, V.; Truffa, S.; Joyo, A.; Voelkers, M.; Alvarez, R.; Sussman, M.A. Notch activation enhances lineage commitment and protective signaling in cardiac progenitor cells. Basic Res Cardiol 2015, 110, 29. doi:10.1007/s00395-015-0488-3.
  88. Wongchana, W.; Palaga, T. Direct regulation of interleukin-6 expression by Notch signaling in macrophages. Cell Mol Immunol 2012, 9, 155-162. doi:10.1038/cmi.2011.36.
  89. Rizzo, P.; Vieceli Dalla Sega, F.; Fortini, F.; Marracino, L.; Rapezzi, C.; Ferrari, R. COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm? Basic Res Cardiol 2020, 115, 31. doi:10.1007/s00395-020-0791-5.
  90. Guo, G.; Ye, L.; Pan, K.; Chen, Y.; Xing, D.; Yan, K.; Chen, Z.; Ding, N.; Li, W.; Huang, H.; Zhang, L.; Li, X.; Xue, X. New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention. Front Cell Dev Biol 2020, 8, 410. doi:10.3389/fcell.2020.00410.
  91. Patel, A.; Jernigan, D.B.; nCo, V.C.D.C.R.T. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep 2020, 69, 140-146. doi:10.15585/mmwr.mm6905e1.
  92. Driggin, E.; Madhavan, M.V.; Bikdeli, B.; Chuich, T.; Laracy, J.; Biondi-Zoccai, G.; Brown, T.S.; Der Nigoghossian, C.; Zidar, D.A.; Haythe, J.; Brodie, D.; Beckman, J.A.; Kirtane, A.J.; Stone, G.W.; Krumholz, H.M.; Parikh, S.A. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol 2020, 75, 2352-2371. doi:10.1016/j.jacc.2020.03.031.
  93. Ng, C.S.; Kasumba, D.M.; Fujita, T.; Luo, H. Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death. Cell Death Differ 2020, 27, 2363-2382. doi:10.1038/s41418-020-0509-0.
  94. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020, 30, 269-271. doi:10.1038/s41422-020-0282-0.
  95. Gordon, C.J.; Tchesnokov, E.P.; Woolner, E.; Perry, J.K.; Feng, J.Y.; Porter, D.P.; Gotte, M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020, 295, 6785-6797. doi:10.1074/jbc.RA120.013679.
  96. Ledford, H. Hopes rise for coronavirus drug remdesivir. Nature 2020, 10.1038/d41586-020-01295-8. doi:10.1038/d41586-020-01295-8.
  97. Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Cao, B.; Wang, C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020, 395, 1569-1578. doi:10.1016/S0140-6736(20)31022-9.
  98. Durante-Mangoni, E.; Andini, R.; Bertolino, L.; Mele, F.; Florio, L.L.; Murino, P.; Corcione, A.; Zampino, R. Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection 2020, 10.1007/s15010-020-01448-x. doi:10.1007/s15010-020-01448-x.
  99. Ferner, R.E.; Aronson, J.K. Remdesivir in covid-19. BMJ 2020, 369, m1610. doi:10.1136/bmj.m1610.
  100. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020, 382, 1787-1799. doi:10.1056/NEJMoa2001282.
  101. Sheahan, T.P.; Sims, A.C.; Leist, S.R.; Schafer, A.; Won, J.; Brown, A.J.; Montgomery, S.A.; Hogg, A.; Babusis, D.; Clarke, M.O.; Spahn, J.E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J.Y.; Cihlar, T.; Jordan, R.; Denison, M.R.; Baric, R.S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020, 11, 222. doi:10.1038/s41467-019-13940-6.
  102. Gan, S.K.; Samaras, K.; Thompson, C.H.; Kraegen, E.W.; Carr, A.; Cooper, D.A.; Chisholm, D.J. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002, 51, 3163-3169. doi:10.2337/diabetes.51.11.3163.
  103. Reyskens, K.M.; Fisher, T.L.; Schisler, J.C.; O'Connor, W.G.; Rogers, A.B.; Willis, M.S.; Planesse, C.; Boyer, F.; Rondeau, P.; Bourdon, E.; Essop, M.F. Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir). PLoS One 2013, 8, e73347. doi:10.1371/journal.pone.0073347.
  104. Giudicessi, J.R.; Noseworthy, P.A.; Friedman, P.A.; Ackerman, M.J. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc 2020, 95, 1213-1221. doi:10.1016/j.mayocp.2020.03.024.
  105. Chu, C.M.; Cheng, V.C.; Hung, I.F.; Wong, M.M.; Chan, K.H.; Chan, K.S.; Kao, R.Y.; Poon, L.L.; Wong, C.L.; Guan, Y.; Peiris, J.S.; Yuen, K.Y.; Group, H.U.S.S. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004, 59, 252-256. doi:10.1136/thorax.2003.012658.
  106. Richardson, P.; Griffin, I.; Tucker, C.; Smith, D.; Oechsle, O.; Phelan, A.; Rawling, M.; Savory, E.; Stebbing, J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020, 395, e30-e31. doi:10.1016/S0140-6736(20)30304-4.
  107. Stebbing, J.; Phelan, A.; Griffin, I.; Tucker, C.; Oechsle, O.; Smith, D.; Richardson, P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020, 20, 400-402. doi:10.1016/S1473-3099(20)30132-8.
  108. Solis-Garcia Del Pozo, J.; Galindo, M.F.; Nava, E.; Jordan, J. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. Eur Rev Med Pharmacol Sci 2020, 24, 7475-7484. doi:10.26355/eurrev_202007_21916.
  109. Della-Torre, E.; Campochiaro, C.; Cavalli, G.; De Luca, G.; Napolitano, A.; La Marca, S.; Boffini, N.; Da Prat, V.; Di Terlizzi, G.; Lanzillotta, M.; Rovere Querini, P.; Ruggeri, A.; Landoni, G.; Tresoldi, M.; Ciceri, F.; Zangrillo, A.; De Cobelli, F.; Dagna, L.; Group, S.-R.S.; members, S.-R.S.G. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020, 10.1136/annrheumdis-2020-218122. doi:10.1136/annrheumdis-2020-218122.
  110. Xu, X.; Han, M.; Li, T.; Sun, W.; Wang, D.; Fu, B.; Zhou, Y.; Zheng, X.; Yang, Y.; Li, X.; Zhang, X.; Pan, A.; Wei, H. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020, 117, 10970-10975. doi:10.1073/pnas.2005615117.
  111. Ledford, H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature 2020, 582, 469. doi:10.1038/d41586-020-01824-5.
  112. Ben-Zvi, I.; Kivity, S.; Langevitz, P.; Shoenfeld, Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012, 42, 145-153. doi:10.1007/s12016-010-8243-x.
  113. Saleh, M.; Gabriels, J.; Chang, D.; Soo Kim, B.; Mansoor, A.; Mahmood, E.; Makker, P.; Ismail, H.; Goldner, B.; Willner, J.; Beldner, S.; Mitra, R.; John, R.; Chinitz, J.; Skipitaris, N.; Mountantonakis, S.; Epstein, L.M. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol 2020, 13, e008662. doi:10.1161/CIRCEP.120.008662.
  114. Rosenberg, E.S.; Dufort, E.M.; Udo, T.; Wilberschied, L.A.; Kumar, J.; Tesoriero, J.; Weinberg, P.; Kirkwood, J.; Muse, A.; DeHovitz, J.; Blog, D.S.; Hutton, B.; Holtgrave, D.R.; Zucker, H.A. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 2020, 10.1001/jama.2020.8630. doi:10.1001/jama.2020.8630.
  115. Mercuro, N.J.; Yen, C.F.; Shim, D.J.; Maher, T.R.; McCoy, C.M.; Zimetbaum, P.J.; Gold, H.S. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020, 10.1001/jamacardio.2020.1834. doi:10.1001/jamacardio.2020.1834.
  116. Geleris, J.; Sun, Y.; Platt, J.; Zucker, J.; Baldwin, M.; Hripcsak, G.; Labella, A.; Manson, D.K.; Kubin, C.; Barr, R.G.; Sobieszczyk, M.E.; Schluger, N.W. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020, 382, 2411-2418. doi:10.1056/NEJMoa2012410.
  117. (FDA), U.S.F.a.D.A. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. 2020, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.
  118. (FDA), U.S.F.a.D.A. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems.
  119. Lurie, N.; Saville, M.; Hatchett, R.; Halton, J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med 2020, 382, 1969-1973. doi:10.1056/NEJMp2005630.
  120. Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; Gao, H.; Ge, X.; Kan, B.; Hu, Y.; Liu, J.; Cai, F.; Jiang, D.; Yin, Y.; Qin, C.; Li, J.; Gong, X.; Lou, X.; Shi, W.; Wu, D.; Zhang, H.; Zhu, L.; Deng, W.; Li, Y.; Lu, J.; Li, C.; Wang, X.; Yin, W.; Zhang, Y.; Qin, C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020, 369, 77-81. doi:10.1126/science.abc1932.
  121. McKay, P.L.a.B. Drugmakers Rush to Develop Vaccines Against China Virus. The Wall Street Journal 2020, https://www.wsj.com/articles/drugmakers-rush-to-develop-vaccines-against-china-virus-11579813026.
  122. Thanh Le, T.; Andreadakis, Z.; Kumar, A.; Gomez Roman, R.; Tollefsen, S.; Saville, M.; Mayhew, S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020, 19, 305-306. doi:10.1038/d41573-020-00073-5.
  123. Jackson, L.A.; Anderson, E.J.; Rouphael, N.G.; Roberts, P.C.; Makhene, M.; Coler, R.N.; McCullough, M.P.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Pruijssers, A.J.; McDermott, A.; Flach, B.; Doria-Rose, N.A.; Corbett, K.S.; Morabito, K.M.; O'Dell, S.; Schmidt, S.D.; Swanson, P.A., 2nd; Padilla, M.; Mascola, J.R.; Neuzil, K.M.; Bennett, H.; Sun, W.; Peters, E.; Makowski, M.; Albert, J.; Cross, K.; Buchanan, W.; Pikaart-Tautges, R.; Ledgerwood, J.E.; Graham, B.S.; Beigel, J.H.; m, R.N.A.S.G. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 2020, 10.1056/NEJMoa2022483. doi:10.1056/NEJMoa2022483.
  124. Moderna, I. Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins. 2020, https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid.
  125. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J.; Hlh Across Speciality Collaboration, U.K. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020, 395, 1033-1034. doi:10.1016/S0140-6736(20)30628-0.
  126. AG, N. Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia. 2020, https://www.novartis.com/news/novartis-announces-plan-initiate-clinical-trial-canakinumab-patients-covid-19-pneumonia.
  127. SE, P.I.a.B. Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program BUSINESS WIRE 2020, https://www.businesswire.com/news/home/20200505005474/en/.
  128. Zhu, F.C.; Li, Y.H.; Guan, X.H.; Hou, L.H.; Wang, W.J.; Li, J.X.; Wu, S.P.; Wang, B.S.; Wang, Z.; Wang, L.; Jia, S.Y.; Jiang, H.D.; Wang, L.; Jiang, T.; Hu, Y.; Gou, J.B.; Xu, S.B.; Xu, J.J.; Wang, X.W.; Wang, W.; Chen, W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020, 395, 1845-1854. doi:10.1016/S0140-6736(20)31208-3.
  129. Smith, T.R.F.; Patel, A.; Ramos, S.; Elwood, D.; Zhu, X.; Yan, J.; Gary, E.N.; Walker, S.N.; Schultheis, K.; Purwar, M.; Xu, Z.; Walters, J.; Bhojnagarwala, P.; Yang, M.; Chokkalingam, N.; Pezzoli, P.; Parzych, E.; Reuschel, E.L.; Doan, A.; Tursi, N.; Vasquez, M.; Choi, J.; Tello-Ruiz, E.; Maricic, I.; Bah, M.A.; Wu, Y.; Amante, D.; Park, D.H.; Dia, Y.; Ali, A.R.; Zaidi, F.I.; Generotti, A.; Kim, K.Y.; Herring, T.A.; Reeder, S.; Andrade, V.M.; Buttigieg, K.; Zhao, G.; Wu, J.M.; Li, D.; Bao, L.; Liu, J.; Deng, W.; Qin, C.; Brown, A.S.; Khoshnejad, M.; Wang, N.; Chu, J.; Wrapp, D.; McLellan, J.S.; Muthumani, K.; Wang, B.; Carroll, M.W.; Kim, J.J.; Boyer, J.; Kulp, D.W.; Humeau, L.; Weiner, D.B.; Broderick, K.E. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 2020, 11, 2601. doi:10.1038/s41467-020-16505-0.
  130. Mahase, E. Covid-19: Russia approves vaccine without large scale testing or published results. BMJ 2020, 370, m3205. doi:10.1136/bmj.m3205.
  131. Logunov, D.Y.; Dolzhikova, I.V.; Zubkova, O.V.; Tukhvatullin, A.I.; Shcheblyakov, D.V.; Dzharullaeva, A.S.; Grousova, D.M.; Erokhova, A.S.; Kovyrshina, A.V.; Botikov, A.G.; Izhaeva, F.M.; Popova, O.; Ozharovskaya, T.A.; Esmagambetov, I.B.; Favorskaya, I.A.; Zrelkin, D.I.; Voronina, D.V.; Shcherbinin, D.N.; Semikhin, A.S.; Simakova, Y.V.; Tokarskaya, E.A.; Lubenets, N.L.; Egorova, D.A.; Shmarov, M.M.; Nikitenko, N.A.; Morozova, L.F.; Smolyarchuk, E.A.; Kryukov, E.V.; Babira, V.F.; Borisevich, S.V.; Naroditsky, B.S.; Gintsburg, A.L. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet 2020, 10.1016/s0140-6736(20)31866-3. doi:10.1016/s0140-6736(20)31866-3.
  132. Zhang, B.; Liu, S.; Tan, T.; Huang, W.; Dong, Y.; Chen, L.; Chen, Q.; Zhang, L.; Zhong, Q.; Zhang, X.; Zou, Y.; Zhang, S. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest 2020, 158, e9-e13. doi:10.1016/j.chest.2020.03.039.
  133. Bloch, E.M.; Shoham, S.; Casadevall, A.; Sachais, B.S.; Shaz, B.; Winters, J.L.; van Buskirk, C.; Grossman, B.J.; Joyner, M.; Henderson, J.P.; Pekosz, A.; Lau, B.; Wesolowski, A.; Katz, L.; Shan, H.; Auwaerter, P.G.; Thomas, D.; Sullivan, D.J.; Paneth, N.; Gehrie, E.; Spitalnik, S.; Hod, E.A.; Pollack, L.; Nicholson, W.T.; Pirofski, L.A.; Bailey, J.A.; Tobian, A.A. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020, 130, 2757-2765. doi:10.1172/JCI138745.
  134. Chen, L.; Xiong, J.; Bao, L.; Shi, Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020, 20, 398-400. doi:10.1016/S1473-3099(20)30141-9.
  135. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Kruger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; Muller, M.A.; Drosten, C.; Pohlmann, S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271-280 e278. doi:10.1016/j.cell.2020.02.052.
  136. Tai, W.; He, L.; Zhang, X.; Pu, J.; Voronin, D.; Jiang, S.; Zhou, Y.; Du, L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020, 17, 613-620. doi:10.1038/s41423-020-0400-4.
  137. Wang, C.; Li, W.; Drabek, D.; Okba, N.M.A.; van Haperen, R.; Osterhaus, A.; van Kuppeveld, F.J.M.; Haagmans, B.L.; Grosveld, F.; Bosch, B.J. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020, 11, 2251. doi:10.1038/s41467-020-16256-y.
  138. Fatima, F.; Ekstrom, K.; Nazarenko, I.; Maugeri, M.; Valadi, H.; Hill, A.F.; Camussi, G.; Nawaz, M. Non-coding RNAs in Mesenchymal Stem Cell-Derived Extracellular Vesicles: Deciphering Regulatory Roles in Stem Cell Potency, Inflammatory Resolve, and Tissue Regeneration. Front Genet 2017, 8, 161. doi:10.3389/fgene.2017.00161.
  139. Rajarshi, K.; Chatterjee, A.; Ray, S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst) 2020, 26, e00467. doi:10.1016/j.btre.2020.e00467.
  140. Chrzanowski, W.; Kim, S.Y.; McClements, L. Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections. Front Bioeng Biotechnol 2020, 8, 554. doi:10.3389/fbioe.2020.00554.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback